These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 23026689)
1. The potential economic value of a human norovirus vaccine for the United States. Bartsch SM; Lopman BA; Hall AJ; Parashar UD; Lee BY Vaccine; 2012 Nov; 30(49):7097-104. PubMed ID: 23026689 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of norovirus vaccination in children in Peru. Mirelman AJ; Ballard SB; Saito M; Kosek MN; Gilman RH Vaccine; 2015 Jun; 33(27):3084-91. PubMed ID: 25980428 [TBL] [Abstract][Full Text] [Related]
3. Epidemiologic challenges in norovirus vaccine development. Hallowell BD; Parashar UD; Hall AJ Hum Vaccin Immunother; 2019; 15(6):1279-1283. PubMed ID: 30481104 [TBL] [Abstract][Full Text] [Related]
4. Duration of immunity to norovirus gastroenteritis. Simmons K; Gambhir M; Leon J; Lopman B Emerg Infect Dis; 2013 Aug; 19(8):1260-7. PubMed ID: 23876612 [TBL] [Abstract][Full Text] [Related]
7. New insights into the global burden of noroviruses and opportunities for prevention. Hall AJ; Glass RI; Parashar UD Expert Rev Vaccines; 2016 Aug; 15(8):949-51. PubMed ID: 27142965 [No Abstract] [Full Text] [Related]
8. A norovirus vaccine on the horizon? Vinjé J J Infect Dis; 2010 Dec; 202(11):1623-5. PubMed ID: 20979457 [No Abstract] [Full Text] [Related]
9. Re-assessing the total burden of norovirus circulating in the United Kingdom population. Harris JP; Iturriza-Gomara M; O'Brien SJ Vaccine; 2017 Feb; 35(6):853-855. PubMed ID: 28094075 [TBL] [Abstract][Full Text] [Related]
10. Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population. Karve S; Krishnarajah G; Korsnes JS; Cassidy A; Candrilli SD Hum Vaccin Immunother; 2014; 10(6):1544-56. PubMed ID: 24732307 [TBL] [Abstract][Full Text] [Related]
11. The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and Control. Lopman BA; Steele D; Kirkwood CD; Parashar UD PLoS Med; 2016 Apr; 13(4):e1001999. PubMed ID: 27115709 [TBL] [Abstract][Full Text] [Related]
12. Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations. Aliabadi N; Lopman BA; Parashar UD; Hall AJ Expert Rev Vaccines; 2015; 14(9):1241-53. PubMed ID: 26224658 [TBL] [Abstract][Full Text] [Related]
13. Global age distribution of pediatric norovirus cases. Shioda K; Kambhampati A; Hall AJ; Lopman BA Vaccine; 2015 Aug; 33(33):4065-8. PubMed ID: 26051514 [TBL] [Abstract][Full Text] [Related]
14. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. Bernstein DI; Atmar RL; Lyon GM; Treanor JJ; Chen WH; Jiang X; Vinjé J; Gregoricus N; Frenck RW; Moe CL; Al-Ibrahim MS; Barrett J; Ferreira J; Estes MK; Graham DY; Goodwin R; Borkowski A; Clemens R; Mendelman PM J Infect Dis; 2015 Mar; 211(6):870-8. PubMed ID: 25210140 [TBL] [Abstract][Full Text] [Related]
15. Clinical profile of children with norovirus disease in rotavirus vaccine era. Wikswo ME; Desai R; Edwards KM; Staat MA; Szilagyi PG; Weinberg GA; Curns AT; Lopman B; Vinjé J; Parashar UD; Payne DC; Hall AJ Emerg Infect Dis; 2013 Oct; 19(10):1691-3. PubMed ID: 24047618 [No Abstract] [Full Text] [Related]
16. Vaccine against norovirus. Tan M; Jiang X Hum Vaccin Immunother; 2014; 10(6):1449-56. PubMed ID: 24718366 [TBL] [Abstract][Full Text] [Related]